See the Directory

A community of peers who have volunteered to independently share their medical experience treating patients with SM and/or taking AYVAKIT® (avapritinib)

Are you interested in sharing your experiences of managing patients living with SM and/or treating patients taking AYVAKIT® (avapritinib) with peers?

SM is a rare disease that can pose unique challenges for healthcare providers (HCPs) due to the limited information available. Blueprint Medicines (“Blueprint”) is compiling an online directory tool (the “Directory”) as a source of demographic and professional information of HCPs who have volunteered to answer questions and advance awareness in the provider community. HCPs who volunteer to be listed in the Directory are not agents of Blueprint for this purpose; any discussions they may have related to this Directory are independent.

What is the SM Provider Peer Directory?

This HCP Directory tool includes the contact information of HCPs who have experience treating patients with SM and/or patients taking AYVAKIT and are willing to discuss their experience with other HCPs. HCP enrollment and participation in the Directory is voluntary, free of charge, and based solely on information provided by the listed HCP. Participation in the Directory is open to all qualifying HCPs and is not contingent upon the recommendation or use of any Blueprint Medicines product.

This Directory is not intended for use by patients or other HCPs to identify potential treating providers. No fees have been received by Blueprint Medicines or paid to HCPs in exchange for listing in this Directory or for any related discussions or services.

By volunteering for inclusion in the SM Provider Peer Directory, you can help raise awareness for this rare disease with the goal of improving care and disease management for patients living with SM.

What do you need to be eligible to be listed in the Directory?

Blueprint asks that registrants, through self-verification, attest that:

  • You are a healthcare provider in good standing
  • Within the past 2 years you have:
    • Seen or managed at least 3 patients with SM (indolent and/or advanced)
      AND/OR
    • Treated at least 2 patients living with SM (indolent and/or advanced) taking AYVAKIT
  • You are willing to speak to peer HCPs who have questions about your relevant medical experience

How will your information be displayed?

Information for HCPs who are listed in the Directory (including contact information) will be displayed and available to US HCPs at SMdirectory.com. Blueprint reserves the right to cease usage of the tool at any time. Should you wish to remove or alter your listing or have questions, please email smhcpdirectory@blueprintmedicines.com.

Interested in registering?

For potential inclusion of your contact information in this directory, please fill out the form below. Please note, participation is voluntary and not compensated. If you register, Blueprint may reach out on a biyearly basis to confirm you wish to continue to be listed and that the information provided is still accurate.

*Indicates required field.

For address details below, please use your institution/practice information.
Please select...
Please select...
Please select...
Please select all that apply. Press control (or command) key + click to select more than 1 option.
Please select...
Please select all that apply. Press control (or command) key + click to select more than 1 option. Your selection(s) will be displayed in the Directory to inform users of the type(s) of SM in which you have experience.
Please select...
Your selection will be displayed in the Directory to inform users if you have clinical experience with AYVAKIT.
Please select...
Please select all that apply. Press control (or command) key + click more than 1 option. This will inform Directory users which contact method is preferred when reaching out.
Please note, NPI numbers will not be listed in the Directory.

Please check the boxes below in order to complete your submission to Blueprint's HCP Directory.*

Stethoscope
The information contained in this site is intended for US healthcare professionals only.

IMPORTANT SAFETY INFORMATION

Intracranial Hemorrhage—Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In AdvSM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 109/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. In ISM patients, no events of ICH occurred in the 246 patients who received any dose of AYVAKIT in the PIONEER study.

Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia.

Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH.

Permanently discontinue AYVAKIT if ICH of any grade occurs. In AdvSM patients, a platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in AdvSM patients with platelet counts <50 x 109/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 109/L by treatment interruption or dose reduction.

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including: 28% of 148 AdvSM patients (3% were Grade ≥3), and 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC (<1% were Grade 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue.

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose.

Adverse Reactions—The most common adverse reactions (≥20%) in patients with AdvSM were edema, diarrhea, nausea, and fatigue/asthenia.

The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with AdvSM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

AYVAKIT is available in 25-mg, 50-mg, 100-mg, and 200-mg tablets.

Please click here to see the full Prescribing Information for AYVAKIT.

INDICATION

AYVAKIT® (avapritinib) is indicated for the treatment of adult patients with:

  • Advanced SM (AdvSM) including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
    Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of <50 x 109/L.
  • Indolent systemic mastocytosis (ISM).
    Limitations of Use: AYVAKIT is not recommended for patients with ISM with platelet counts of <50 x 109/L.

IMPORTANT SAFETY INFORMATION

Intracranial Hemorrhage—Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. Overall, ICH (eg, subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In AdvSM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts ≥50 x 109/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts. In ISM patients, no events of ICH occurred in the 246 patients who received any dose of AYVAKIT in the PIONEER study.

Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia.

Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH.

Permanently discontinue AYVAKIT if ICH of any grade occurs. In AdvSM patients, a platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in AdvSM patients with platelet counts <50 x 109/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 109/L by treatment interruption or dose reduction.

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including: 28% of 148 AdvSM patients (3% were Grade ≥3), and 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC (<1% were Grade 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue.

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective method of contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks after the final dose.

Adverse Reactions—The most common adverse reactions (≥20%) in patients with AdvSM were edema, diarrhea, nausea, and fatigue/asthenia.

The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided in patients with AdvSM, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

AYVAKIT is available in 25-mg, 50-mg, 100-mg, and 200-mg tablets.

Please click here to see the full Prescribing Information for AYVAKIT.

INDICATION

AYVAKIT® (avapritinib) is indicated for the treatment of adult patients with:

  • Advanced SM (AdvSM) including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
    Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of <50 x 109/L.
  • Indolent systemic mastocytosis (ISM).
    Limitations of Use: AYVAKIT is not recommended for patients with ISM with platelet counts of <50 x 109/L.